IRCT201504211556N76已完成4 期
Pregnenolone in the treatment of women with chronic schizophrenia: a double blind randomized trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 45 years（—）
- 性别
- Female
入选标准
- •1-women with Diagnosis of Schizophrenia based on DSM- 5 criteria; 2- Minimum Score of 60 on Positive and Negative Scale; 3- Age between 18-45; 4-Chronic Schizophrenia- duration of the disorder more than 2 years; 5-Minimum score of 20 in negative sub score. Exclusion criteria: 1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4-receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month; 5-receiving ECT during the last 14 days ; 6-Hepatic and renal diseases; 7- History of thromboembolism ; 8- History of abnormal uterine bleeding, uterine or breast canser; 9-CVA; 10-Hormone replacement therapy; 11- Endocrine abnormality.
排除标准
- 未提供
研究者
相似试验
招募中
1 期
PREMI trialnexplained recurrent miscarriagesMedDRA version: 21.1Level: LLTClassification code: 10038104Term: Recurrent abortion Class: 10036585CTIS2023-503220-76-01eiden University Medical Center490
招募中
3 期
Efficacy of pregnenolon in treatment of irritability inteeanagers with autismAutistic disorder.Autistic disorderF84.0IRCT20090117001556N112Tehran University of Medical Sciences40
已完成
1 期
Development of Pregnenolone as a Treatment for DepressionMajor Depressive DisorderNCT03645096University of Texas Southwestern Medical Center34
进行中（未招募）
1 期
Optimization of treatment for patients with chronic hepatitis C infected with a particular virus type (HCV-genotype 2 or 3): 12 vs. 24 weeks of treatment extension for patients with slow response to therapyEUCTR2008-000706-36-DEHannover Medical School; Competence Network Viral Hepatitis (Hep-Net)150
进行中（未招募）
1 期
First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: A randomised, double-blind, placebo-controlled, multi-centre trial [The PROMISE (PROgesterone in recurrent MIScarriagE) Trial] Funded by NIHR-HTA(UK) 08/38/01 for £1.2million - Progesterone in Recurrent Miscarriages (PROMISE) StudyRecurrent MiscarriageEUCTR2009-011208-42-GBImperial College, London836